GUTS Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to dura…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance Fractyl Health (NASDAQ:GUTS) outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines. The company said Revita is designed for post-GLP- | ||
 Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day Fractyl Health (NASDAQ:GUTS) shares rose 2. 8% in pre-market trading ahead of the company’s Virtual Commercial Strategy Day, scheduled for 11:00 AM ET on Tuesday. | ||
Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial Fractyl Health (NASDAQ:GUTS) is advancing two one-time treatment approaches intended to provide durable benefits for obesity, type 2 diabetes and related metabolic diseases, Chief Executive Officer Harith Rajagopalan said during a Canaccord discussion. The company’s lead program, Revita, uses an ou | ||
 Fractyl Health, Inc. Common Stock Q2 2026 Earnings Call Summary Moby summary of Fractyl Health, Inc. Common Stock's Q2 2026 earnings call | ||
Fractyl Health Inc (GUTS) (Q2 2026) Earnings Call Highlights: Pivotal Data on Track and ... Fractyl Health Inc (GUTS) reports strong REMAIN-1 results, a clear regulatory path for Revita, and a cash runway into early 2027. | ||
 Fractyl Health Q2 Earnings Call Highlights Fractyl Health (NASDAQ:GUTS) said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and pursue a potential FDA De Novo submission l | ||
 Fractyl Health Stock Up on Encouraging One-Year Revita Study Results GUTS' shares surge after Revita patients retain up to 84% of GLP-1-induced weight loss in a year, compared with 46% for sham patients. | ||
Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s Fractyl Health (NASDAQ:GUTS) reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its Revita procedure helped patients maintain a larger share of GLP-1-induced weight loss after discontinuing GLP-1 therapy compared with a sham procedure. On the company’s data cal | ||